Overview
Mendra, a newly launched biopharmaceutical company focused on rare diseases, has secured an oversubscribed $82 million Series A funding round. This financing aims to acquire, develop, and commercialize therapies for high-unmet-need indications. The round was co-led by OrbiMed, 8VC, and 5AM Ventures, with additional participation from Lux Capital and Wing VC.
Products
Loading...
Recent Deals
$82M
Investors: OrbiMed, 8VC, 5AM Ventures, Lux Capital, Wing VC
Mendra, a newly launched biopharmaceutical company focused on rare diseases, has secured an oversubscribed $82 million Series A funding round. This financing aims to acquire, develop, and commercialize therapies for high-unmet-need indications. The round was co-led by OrbiMed, 8VC, and 5AM Ventures, with additional participation from Lux Capital and Wing VC.